NLTX
Neoleukin Therapeutics, Inc. [NLTX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NLTX Stock Summary
In the News
NLTX Financial details
Company Rating
-
Market Cap
8.2M
Income
-39.36M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
18 Mar 2024
P/E
-0.98
Forward P/E
-
PEG
-0.07
P/S
-
P/B
0.51
P/C
-
P/FCF
-0.25
Quick Ratio
15.06
Current Ratio
15.33
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.64
EPS next Y
-
EPS next Q
-
EPS this Y
-4.72%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-5.5%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
115.79%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-44%
ROE
-48%
ROC
-0.45%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.42-18.8
52W High
-
52W Low
-
RSI
-
Rel Volume
19.76
Avg Volume
5.52K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.102
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 5.52K
- Market Capitalization 8.2M
- Employee 7
- CEO Ms. Donna M. Cochener-Metcalfe J.D.
- Headquarters Seattle,WA,US
- IPO Date 2014-03-07
-
Website
https://www.neoleukin.com 
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
